biotech
Anticancer Drug Against Hodgkin's and Leukemia Granted Orphan Drug Status
Filed in archive Drugs, Vaccines and Therapeutics by ruth on January 31, 2006
Understanding Leukemias, Lymphomas and Myelomas

The European Commission has granted an orphan drug designation to an investigational anticancer drug, 1D09C3, developed for the treatment of Hodgkin's lymphoma and chronic lymphocytic leukemia.

1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. 1D09C3 binds to MHC class II molecules on the surface of cells and selectively kills activated, proliferating tumor cells, which include B-cell and T-cell lymphomas.


1D09C3 is the first internal research program to advance into human trials by GPC Biotech, a Germany-based firm focusing on oncology. Read the full press release from GPC Biotech.

Permalink: Anticancer Drug Against Hodgkin's and Leukemia Granted Orphan Drug Status
Tags: hodgkin  leukemia  drug  biotech  orphan  orphan+drug  granted+orphan  drug+status 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/14752
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Anticancer Drug Against Hodgkin's and Leukemia Granted Orphan Drug Status:

  • Currently 8.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.00 out of 1 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!